nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—ABCC1—Mitoxantrone—multiple sclerosis	0.153	0.207	CbGbCtD
Atazanavir—SLCO1B3—Methotrexate—multiple sclerosis	0.0922	0.125	CbGbCtD
Atazanavir—ABCC1—Methotrexate—multiple sclerosis	0.0637	0.0864	CbGbCtD
Atazanavir—ABCB1—Methylprednisolone—multiple sclerosis	0.0506	0.0686	CbGbCtD
Atazanavir—CYP3A4—Fingolimod—multiple sclerosis	0.047	0.0637	CbGbCtD
Atazanavir—ABCB1—Mitoxantrone—multiple sclerosis	0.0369	0.05	CbGbCtD
Atazanavir—ABCB1—Betamethasone—multiple sclerosis	0.0329	0.0446	CbGbCtD
Atazanavir—ABCB1—Prednisolone—multiple sclerosis	0.0325	0.044	CbGbCtD
Atazanavir—ABCB1—Prednisone—multiple sclerosis	0.0306	0.0415	CbGbCtD
Atazanavir—CYP3A4—Methylprednisolone—multiple sclerosis	0.0303	0.0411	CbGbCtD
Atazanavir—CYP3A4—Triamcinolone—multiple sclerosis	0.023	0.0311	CbGbCtD
Atazanavir—CYP3A4—Mitoxantrone—multiple sclerosis	0.0221	0.03	CbGbCtD
Atazanavir—CYP2C9—Dexamethasone—multiple sclerosis	0.0197	0.0267	CbGbCtD
Atazanavir—CYP3A4—Betamethasone—multiple sclerosis	0.0197	0.0267	CbGbCtD
Atazanavir—CYP3A4—Prednisolone—multiple sclerosis	0.0194	0.0264	CbGbCtD
Atazanavir—ABCB1—Dexamethasone—multiple sclerosis	0.0191	0.0259	CbGbCtD
Atazanavir—CYP3A4—Prednisone—multiple sclerosis	0.0184	0.0249	CbGbCtD
Atazanavir—ABCB1—Methotrexate—multiple sclerosis	0.0154	0.0208	CbGbCtD
Atazanavir—CYP3A4—Dexamethasone—multiple sclerosis	0.0115	0.0155	CbGbCtD
Atazanavir—ABCC1—S1P1 pathway—S1PR1—multiple sclerosis	0.000468	0.0753	CbGpPWpGaD
Atazanavir—ABCC1—Sphingosine 1-phosphate (S1P) pathway—S1PR1—multiple sclerosis	0.000432	0.0695	CbGpPWpGaD
Atazanavir—ABCC1—Irinotecan Pathway—BCHE—multiple sclerosis	0.000277	0.0445	CbGpPWpGaD
Atazanavir—SLCO1B3—Transport of organic anions—ALB—multiple sclerosis	0.000224	0.036	CbGpPWpGaD
Atazanavir—Depression—Methotrexate—multiple sclerosis	0.00018	0.000703	CcSEcCtD
Atazanavir—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00018	0.000702	CcSEcCtD
Atazanavir—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00018	0.000702	CcSEcCtD
Atazanavir—Discomfort—Triamcinolone—multiple sclerosis	0.00018	0.000702	CcSEcCtD
Atazanavir—Discomfort—Methylprednisolone—multiple sclerosis	0.000179	0.0007	CcSEcCtD
Atazanavir—Headache—Azathioprine—multiple sclerosis	0.000179	0.000699	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000179	0.000699	CcSEcCtD
Atazanavir—Dry mouth—Triamcinolone—multiple sclerosis	0.000178	0.000695	CcSEcCtD
Atazanavir—Renal failure—Methotrexate—multiple sclerosis	0.000177	0.000693	CcSEcCtD
Atazanavir—Angioedema—Dexamethasone—multiple sclerosis	0.000177	0.000692	CcSEcCtD
Atazanavir—Angioedema—Betamethasone—multiple sclerosis	0.000177	0.000692	CcSEcCtD
Atazanavir—Stomatitis—Methotrexate—multiple sclerosis	0.000176	0.000687	CcSEcCtD
Atazanavir—Angiopathy—Prednisone—multiple sclerosis	0.000176	0.000687	CcSEcCtD
Atazanavir—Confusional state—Methylprednisolone—multiple sclerosis	0.000175	0.000685	CcSEcCtD
Atazanavir—Immune system disorder—Prednisone—multiple sclerosis	0.000175	0.000684	CcSEcCtD
Atazanavir—Malaise—Dexamethasone—multiple sclerosis	0.000175	0.000683	CcSEcCtD
Atazanavir—Malaise—Betamethasone—multiple sclerosis	0.000175	0.000683	CcSEcCtD
Atazanavir—Oedema—Triamcinolone—multiple sclerosis	0.000174	0.000681	CcSEcCtD
Atazanavir—Syncope—Dexamethasone—multiple sclerosis	0.000174	0.000679	CcSEcCtD
Atazanavir—Syncope—Betamethasone—multiple sclerosis	0.000174	0.000679	CcSEcCtD
Atazanavir—Infection—Triamcinolone—multiple sclerosis	0.000173	0.000677	CcSEcCtD
Atazanavir—Sweating—Methotrexate—multiple sclerosis	0.000173	0.000676	CcSEcCtD
Atazanavir—Infection—Methylprednisolone—multiple sclerosis	0.000173	0.000675	CcSEcCtD
Atazanavir—Haematuria—Methotrexate—multiple sclerosis	0.000172	0.000672	CcSEcCtD
Atazanavir—Shock—Triamcinolone—multiple sclerosis	0.000171	0.00067	CcSEcCtD
Atazanavir—Insomnia—Prednisolone—multiple sclerosis	0.000171	0.00067	CcSEcCtD
Atazanavir—Alopecia—Prednisone—multiple sclerosis	0.000171	0.000669	CcSEcCtD
Atazanavir—Shock—Methylprednisolone—multiple sclerosis	0.000171	0.000669	CcSEcCtD
Atazanavir—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000171	0.000667	CcSEcCtD
Atazanavir—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000171	0.000666	CcSEcCtD
Atazanavir—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00017	0.000665	CcSEcCtD
Atazanavir—Loss of consciousness—Betamethasone—multiple sclerosis	0.00017	0.000665	CcSEcCtD
Atazanavir—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00017	0.000665	CcSEcCtD
Atazanavir—Mental disorder—Prednisone—multiple sclerosis	0.00017	0.000664	CcSEcCtD
Atazanavir—Nausea—Azathioprine—multiple sclerosis	0.00017	0.000663	CcSEcCtD
Atazanavir—Skin disorder—Methylprednisolone—multiple sclerosis	0.000169	0.00066	CcSEcCtD
Atazanavir—Malnutrition—Prednisone—multiple sclerosis	0.000169	0.000659	CcSEcCtD
Atazanavir—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000168	0.000658	CcSEcCtD
Atazanavir—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000168	0.000657	CcSEcCtD
Atazanavir—Convulsion—Betamethasone—multiple sclerosis	0.000168	0.000656	CcSEcCtD
Atazanavir—Convulsion—Dexamethasone—multiple sclerosis	0.000168	0.000656	CcSEcCtD
Atazanavir—Hypertension—Dexamethasone—multiple sclerosis	0.000167	0.000654	CcSEcCtD
Atazanavir—Hypertension—Betamethasone—multiple sclerosis	0.000167	0.000654	CcSEcCtD
Atazanavir—SLCO1B3—Recycling of bile acids and salts—ALB—multiple sclerosis	0.000166	0.0267	CbGpPWpGaD
Atazanavir—Asthenia—Mitoxantrone—multiple sclerosis	0.000166	0.000648	CcSEcCtD
Atazanavir—Myalgia—Dexamethasone—multiple sclerosis	0.000165	0.000645	CcSEcCtD
Atazanavir—Myalgia—Betamethasone—multiple sclerosis	0.000165	0.000645	CcSEcCtD
Atazanavir—Anxiety—Betamethasone—multiple sclerosis	0.000164	0.000642	CcSEcCtD
Atazanavir—Anxiety—Dexamethasone—multiple sclerosis	0.000164	0.000642	CcSEcCtD
Atazanavir—Discomfort—Betamethasone—multiple sclerosis	0.000163	0.000637	CcSEcCtD
Atazanavir—Discomfort—Dexamethasone—multiple sclerosis	0.000163	0.000637	CcSEcCtD
Atazanavir—Pain—Prednisolone—multiple sclerosis	0.000162	0.000633	CcSEcCtD
Atazanavir—Hepatitis—Methotrexate—multiple sclerosis	0.000162	0.000633	CcSEcCtD
Atazanavir—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00016	0.000625	CcSEcCtD
Atazanavir—Urethral disorder—Methotrexate—multiple sclerosis	0.000159	0.000621	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000159	0.00062	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000158	0.000619	CcSEcCtD
Atazanavir—Oedema—Betamethasone—multiple sclerosis	0.000158	0.000618	CcSEcCtD
Atazanavir—Oedema—Dexamethasone—multiple sclerosis	0.000158	0.000618	CcSEcCtD
Atazanavir—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000158	0.000618	CcSEcCtD
Atazanavir—Insomnia—Triamcinolone—multiple sclerosis	0.000158	0.000616	CcSEcCtD
Atazanavir—Insomnia—Methylprednisolone—multiple sclerosis	0.000157	0.000615	CcSEcCtD
Atazanavir—Infection—Dexamethasone—multiple sclerosis	0.000157	0.000614	CcSEcCtD
Atazanavir—Infection—Betamethasone—multiple sclerosis	0.000157	0.000614	CcSEcCtD
Atazanavir—Ill-defined disorder—Prednisone—multiple sclerosis	0.000157	0.000612	CcSEcCtD
Atazanavir—Feeling abnormal—Prednisolone—multiple sclerosis	0.000156	0.00061	CcSEcCtD
Atazanavir—Shock—Betamethasone—multiple sclerosis	0.000156	0.000608	CcSEcCtD
Atazanavir—Shock—Dexamethasone—multiple sclerosis	0.000156	0.000608	CcSEcCtD
Atazanavir—Dyspnoea—Triamcinolone—multiple sclerosis	0.000155	0.000607	CcSEcCtD
Atazanavir—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000155	0.000606	CcSEcCtD
Atazanavir—Nervous system disorder—Betamethasone—multiple sclerosis	0.000155	0.000606	CcSEcCtD
Atazanavir—Agitation—Prednisone—multiple sclerosis	0.000155	0.000606	CcSEcCtD
Atazanavir—Angioedema—Prednisone—multiple sclerosis	0.000154	0.000602	CcSEcCtD
Atazanavir—Dyspepsia—Triamcinolone—multiple sclerosis	0.000153	0.000599	CcSEcCtD
Atazanavir—Erythema multiforme—Methotrexate—multiple sclerosis	0.000153	0.000599	CcSEcCtD
Atazanavir—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000153	0.000598	CcSEcCtD
Atazanavir—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000153	0.000597	CcSEcCtD
Atazanavir—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000153	0.000597	CcSEcCtD
Atazanavir—Malaise—Prednisone—multiple sclerosis	0.000152	0.000595	CcSEcCtD
Atazanavir—Eye disorder—Methotrexate—multiple sclerosis	0.000151	0.000592	CcSEcCtD
Atazanavir—Syncope—Prednisone—multiple sclerosis	0.000151	0.000591	CcSEcCtD
Atazanavir—Tinnitus—Methotrexate—multiple sclerosis	0.000151	0.00059	CcSEcCtD
Atazanavir—Anorexia—Dexamethasone—multiple sclerosis	0.000151	0.000589	CcSEcCtD
Atazanavir—Anorexia—Betamethasone—multiple sclerosis	0.000151	0.000589	CcSEcCtD
Atazanavir—Urticaria—Prednisolone—multiple sclerosis	0.000151	0.000588	CcSEcCtD
Atazanavir—Cardiac disorder—Methotrexate—multiple sclerosis	0.00015	0.000587	CcSEcCtD
Atazanavir—Fatigue—Triamcinolone—multiple sclerosis	0.00015	0.000587	CcSEcCtD
Atazanavir—Fatigue—Methylprednisolone—multiple sclerosis	0.00015	0.000586	CcSEcCtD
Atazanavir—Pain—Triamcinolone—multiple sclerosis	0.000149	0.000582	CcSEcCtD
Atazanavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000149	0.0239	CbGpPWpGaD
Atazanavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000149	0.0239	CbGpPWpGaD
Atazanavir—Loss of consciousness—Prednisone—multiple sclerosis	0.000148	0.00058	CcSEcCtD
Atazanavir—Angiopathy—Methotrexate—multiple sclerosis	0.000147	0.000574	CcSEcCtD
Atazanavir—Vomiting—Mitoxantrone—multiple sclerosis	0.000147	0.000574	CcSEcCtD
Atazanavir—Immune system disorder—Methotrexate—multiple sclerosis	0.000146	0.000572	CcSEcCtD
Atazanavir—Convulsion—Prednisone—multiple sclerosis	0.000146	0.000571	CcSEcCtD
Atazanavir—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000146	0.00057	CcSEcCtD
Atazanavir—Hypertension—Prednisone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Atazanavir—Rash—Mitoxantrone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Atazanavir—Dermatitis—Mitoxantrone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Atazanavir—Headache—Mitoxantrone—multiple sclerosis	0.000145	0.000565	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000144	0.000563	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000144	0.000563	CcSEcCtD
Atazanavir—Arthralgia—Prednisone—multiple sclerosis	0.000144	0.000561	CcSEcCtD
Atazanavir—Myalgia—Prednisone—multiple sclerosis	0.000144	0.000561	CcSEcCtD
Atazanavir—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000144	0.000561	CcSEcCtD
Atazanavir—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000143	0.00056	CcSEcCtD
Atazanavir—Anxiety—Prednisone—multiple sclerosis	0.000143	0.000559	CcSEcCtD
Atazanavir—Alopecia—Methotrexate—multiple sclerosis	0.000143	0.000559	CcSEcCtD
Atazanavir—Insomnia—Betamethasone—multiple sclerosis	0.000143	0.000559	CcSEcCtD
Atazanavir—Insomnia—Dexamethasone—multiple sclerosis	0.000143	0.000559	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000143	0.000557	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000142	0.000556	CcSEcCtD
Atazanavir—Discomfort—Prednisone—multiple sclerosis	0.000142	0.000555	CcSEcCtD
Atazanavir—Mental disorder—Methotrexate—multiple sclerosis	0.000142	0.000555	CcSEcCtD
Atazanavir—Malnutrition—Methotrexate—multiple sclerosis	0.000141	0.000551	CcSEcCtD
Atazanavir—Hypersensitivity—Prednisolone—multiple sclerosis	0.00014	0.000546	CcSEcCtD
Atazanavir—Dyspepsia—Betamethasone—multiple sclerosis	0.000139	0.000544	CcSEcCtD
Atazanavir—Dyspepsia—Dexamethasone—multiple sclerosis	0.000139	0.000544	CcSEcCtD
Atazanavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000139	0.0224	CbGpPWpGaD
Atazanavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000139	0.0224	CbGpPWpGaD
Atazanavir—Urticaria—Triamcinolone—multiple sclerosis	0.000138	0.000541	CcSEcCtD
Atazanavir—Urticaria—Methylprednisolone—multiple sclerosis	0.000138	0.00054	CcSEcCtD
Atazanavir—Dysgeusia—Methotrexate—multiple sclerosis	0.000138	0.00054	CcSEcCtD
Atazanavir—Body temperature increased—Triamcinolone—multiple sclerosis	0.000138	0.000538	CcSEcCtD
Atazanavir—Oedema—Prednisone—multiple sclerosis	0.000138	0.000538	CcSEcCtD
Atazanavir—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000137	0.000537	CcSEcCtD
Atazanavir—Decreased appetite—Dexamethasone—multiple sclerosis	0.000137	0.000537	CcSEcCtD
Atazanavir—Decreased appetite—Betamethasone—multiple sclerosis	0.000137	0.000537	CcSEcCtD
Atazanavir—Nausea—Mitoxantrone—multiple sclerosis	0.000137	0.000536	CcSEcCtD
Atazanavir—Infection—Prednisone—multiple sclerosis	0.000137	0.000535	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000137	0.000533	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000137	0.000533	CcSEcCtD
Atazanavir—Back pain—Methotrexate—multiple sclerosis	0.000136	0.000533	CcSEcCtD
Atazanavir—Fatigue—Dexamethasone—multiple sclerosis	0.000136	0.000533	CcSEcCtD
Atazanavir—Fatigue—Betamethasone—multiple sclerosis	0.000136	0.000533	CcSEcCtD
Atazanavir—Shock—Prednisone—multiple sclerosis	0.000135	0.000529	CcSEcCtD
Atazanavir—Pain—Betamethasone—multiple sclerosis	0.000135	0.000528	CcSEcCtD
Atazanavir—Pain—Dexamethasone—multiple sclerosis	0.000135	0.000528	CcSEcCtD
Atazanavir—Nervous system disorder—Prednisone—multiple sclerosis	0.000135	0.000528	CcSEcCtD
Atazanavir—Skin disorder—Prednisone—multiple sclerosis	0.000134	0.000523	CcSEcCtD
Atazanavir—Hyperhidrosis—Prednisone—multiple sclerosis	0.000133	0.00052	CcSEcCtD
Atazanavir—Anorexia—Prednisone—multiple sclerosis	0.000131	0.000513	CcSEcCtD
Atazanavir—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000131	0.000511	CcSEcCtD
Atazanavir—Feeling abnormal—Betamethasone—multiple sclerosis	0.00013	0.000509	CcSEcCtD
Atazanavir—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00013	0.000509	CcSEcCtD
Atazanavir—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000129	0.000505	CcSEcCtD
Atazanavir—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000129	0.000505	CcSEcCtD
Atazanavir—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000128	0.000502	CcSEcCtD
Atazanavir—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000128	0.000501	CcSEcCtD
Atazanavir—Malaise—Methotrexate—multiple sclerosis	0.000127	0.000497	CcSEcCtD
Atazanavir—Urticaria—Dexamethasone—multiple sclerosis	0.000126	0.000491	CcSEcCtD
Atazanavir—Urticaria—Betamethasone—multiple sclerosis	0.000126	0.000491	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000125	0.00049	CcSEcCtD
Atazanavir—Dizziness—Prednisolone—multiple sclerosis	0.000125	0.00049	CcSEcCtD
Atazanavir—Asthenia—Triamcinolone—multiple sclerosis	0.000125	0.000489	CcSEcCtD
Atazanavir—Body temperature increased—Betamethasone—multiple sclerosis	0.000125	0.000488	CcSEcCtD
Atazanavir—Abdominal pain—Dexamethasone—multiple sclerosis	0.000125	0.000488	CcSEcCtD
Atazanavir—Body temperature increased—Dexamethasone—multiple sclerosis	0.000125	0.000488	CcSEcCtD
Atazanavir—Abdominal pain—Betamethasone—multiple sclerosis	0.000125	0.000488	CcSEcCtD
Atazanavir—Asthenia—Methylprednisolone—multiple sclerosis	0.000125	0.000488	CcSEcCtD
Atazanavir—Insomnia—Prednisone—multiple sclerosis	0.000125	0.000487	CcSEcCtD
Atazanavir—Pruritus—Triamcinolone—multiple sclerosis	0.000123	0.000482	CcSEcCtD
Atazanavir—Cough—Methotrexate—multiple sclerosis	0.000123	0.000481	CcSEcCtD
Atazanavir—Pruritus—Methylprednisolone—multiple sclerosis	0.000123	0.000481	CcSEcCtD
Atazanavir—Convulsion—Methotrexate—multiple sclerosis	0.000122	0.000477	CcSEcCtD
Atazanavir—Dyspepsia—Prednisone—multiple sclerosis	0.000121	0.000474	CcSEcCtD
Atazanavir—Chest pain—Methotrexate—multiple sclerosis	0.00012	0.000469	CcSEcCtD
Atazanavir—Myalgia—Methotrexate—multiple sclerosis	0.00012	0.000469	CcSEcCtD
Atazanavir—Arthralgia—Methotrexate—multiple sclerosis	0.00012	0.000469	CcSEcCtD
Atazanavir—Decreased appetite—Prednisone—multiple sclerosis	0.00012	0.000468	CcSEcCtD
Atazanavir—Rash—Prednisolone—multiple sclerosis	0.000119	0.000467	CcSEcCtD
Atazanavir—Dermatitis—Prednisolone—multiple sclerosis	0.000119	0.000466	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000119	0.000466	CcSEcCtD
Atazanavir—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000119	0.000465	CcSEcCtD
Atazanavir—Fatigue—Prednisone—multiple sclerosis	0.000119	0.000464	CcSEcCtD
Atazanavir—Headache—Prednisolone—multiple sclerosis	0.000119	0.000464	CcSEcCtD
Atazanavir—Discomfort—Methotrexate—multiple sclerosis	0.000119	0.000464	CcSEcCtD
Atazanavir—Constipation—Prednisone—multiple sclerosis	0.000118	0.00046	CcSEcCtD
Atazanavir—Confusional state—Methotrexate—multiple sclerosis	0.000116	0.000453	CcSEcCtD
Atazanavir—Dizziness—Triamcinolone—multiple sclerosis	0.000115	0.00045	CcSEcCtD
Atazanavir—Dizziness—Methylprednisolone—multiple sclerosis	0.000115	0.000449	CcSEcCtD
Atazanavir—Infection—Methotrexate—multiple sclerosis	0.000114	0.000447	CcSEcCtD
Atazanavir—Feeling abnormal—Prednisone—multiple sclerosis	0.000113	0.000443	CcSEcCtD
Atazanavir—Asthenia—Betamethasone—multiple sclerosis	0.000113	0.000443	CcSEcCtD
Atazanavir—Asthenia—Dexamethasone—multiple sclerosis	0.000113	0.000443	CcSEcCtD
Atazanavir—Nervous system disorder—Methotrexate—multiple sclerosis	0.000113	0.000441	CcSEcCtD
Atazanavir—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000113	0.00044	CcSEcCtD
Atazanavir—Nausea—Prednisolone—multiple sclerosis	0.000113	0.00044	CcSEcCtD
Atazanavir—Pruritus—Betamethasone—multiple sclerosis	0.000112	0.000437	CcSEcCtD
Atazanavir—Pruritus—Dexamethasone—multiple sclerosis	0.000112	0.000437	CcSEcCtD
Atazanavir—Skin disorder—Methotrexate—multiple sclerosis	0.000112	0.000437	CcSEcCtD
Atazanavir—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000111	0.000435	CcSEcCtD
Atazanavir—Vomiting—Triamcinolone—multiple sclerosis	0.000111	0.000433	CcSEcCtD
Atazanavir—Vomiting—Methylprednisolone—multiple sclerosis	0.000111	0.000432	CcSEcCtD
Atazanavir—Rash—Triamcinolone—multiple sclerosis	0.00011	0.000429	CcSEcCtD
Atazanavir—Dermatitis—Triamcinolone—multiple sclerosis	0.00011	0.000429	CcSEcCtD
Atazanavir—Anorexia—Methotrexate—multiple sclerosis	0.00011	0.000429	CcSEcCtD
Atazanavir—Rash—Methylprednisolone—multiple sclerosis	0.00011	0.000428	CcSEcCtD
Atazanavir—Dermatitis—Methylprednisolone—multiple sclerosis	0.00011	0.000428	CcSEcCtD
Atazanavir—Urticaria—Prednisone—multiple sclerosis	0.000109	0.000427	CcSEcCtD
Atazanavir—Headache—Triamcinolone—multiple sclerosis	0.000109	0.000427	CcSEcCtD
Atazanavir—Headache—Methylprednisolone—multiple sclerosis	0.000109	0.000426	CcSEcCtD
Atazanavir—Body temperature increased—Prednisone—multiple sclerosis	0.000109	0.000425	CcSEcCtD
Atazanavir—Abdominal pain—Prednisone—multiple sclerosis	0.000109	0.000425	CcSEcCtD
Atazanavir—Diarrhoea—Dexamethasone—multiple sclerosis	0.000108	0.000423	CcSEcCtD
Atazanavir—Diarrhoea—Betamethasone—multiple sclerosis	0.000108	0.000423	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000105	0.00041	CcSEcCtD
Atazanavir—Dizziness—Betamethasone—multiple sclerosis	0.000105	0.000409	CcSEcCtD
Atazanavir—Dizziness—Dexamethasone—multiple sclerosis	0.000105	0.000409	CcSEcCtD
Atazanavir—Insomnia—Methotrexate—multiple sclerosis	0.000104	0.000407	CcSEcCtD
Atazanavir—Nausea—Triamcinolone—multiple sclerosis	0.000104	0.000405	CcSEcCtD
Atazanavir—Nausea—Methylprednisolone—multiple sclerosis	0.000103	0.000404	CcSEcCtD
Atazanavir—Dyspnoea—Methotrexate—multiple sclerosis	0.000103	0.000401	CcSEcCtD
Atazanavir—Somnolence—Methotrexate—multiple sclerosis	0.000102	0.0004	CcSEcCtD
Atazanavir—Hypersensitivity—Prednisone—multiple sclerosis	0.000101	0.000396	CcSEcCtD
Atazanavir—Dyspepsia—Methotrexate—multiple sclerosis	0.000101	0.000396	CcSEcCtD
Atazanavir—Vomiting—Dexamethasone—multiple sclerosis	0.000101	0.000393	CcSEcCtD
Atazanavir—Vomiting—Betamethasone—multiple sclerosis	0.000101	0.000393	CcSEcCtD
Atazanavir—Decreased appetite—Methotrexate—multiple sclerosis	0.0001	0.000391	CcSEcCtD
Atazanavir—Rash—Dexamethasone—multiple sclerosis	9.97e-05	0.00039	CcSEcCtD
Atazanavir—Rash—Betamethasone—multiple sclerosis	9.97e-05	0.00039	CcSEcCtD
Atazanavir—Dermatitis—Betamethasone—multiple sclerosis	9.96e-05	0.000389	CcSEcCtD
Atazanavir—Dermatitis—Dexamethasone—multiple sclerosis	9.96e-05	0.000389	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.94e-05	0.000388	CcSEcCtD
Atazanavir—Fatigue—Methotrexate—multiple sclerosis	9.92e-05	0.000388	CcSEcCtD
Atazanavir—Headache—Betamethasone—multiple sclerosis	9.91e-05	0.000387	CcSEcCtD
Atazanavir—Headache—Dexamethasone—multiple sclerosis	9.91e-05	0.000387	CcSEcCtD
Atazanavir—Asthenia—Prednisone—multiple sclerosis	9.88e-05	0.000386	CcSEcCtD
Atazanavir—Pain—Methotrexate—multiple sclerosis	9.84e-05	0.000385	CcSEcCtD
Atazanavir—Pruritus—Prednisone—multiple sclerosis	9.74e-05	0.000381	CcSEcCtD
Atazanavir—Feeling abnormal—Methotrexate—multiple sclerosis	9.48e-05	0.000371	CcSEcCtD
Atazanavir—Diarrhoea—Prednisone—multiple sclerosis	9.42e-05	0.000368	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methotrexate—multiple sclerosis	9.41e-05	0.000368	CcSEcCtD
Atazanavir—Nausea—Betamethasone—multiple sclerosis	9.39e-05	0.000367	CcSEcCtD
Atazanavir—Nausea—Dexamethasone—multiple sclerosis	9.39e-05	0.000367	CcSEcCtD
Atazanavir—SLCO1B3—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	9.34e-05	0.015	CbGpPWpGaD
Atazanavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	9.16e-05	0.0147	CbGpPWpGaD
Atazanavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	9.16e-05	0.0147	CbGpPWpGaD
Atazanavir—Urticaria—Methotrexate—multiple sclerosis	9.14e-05	0.000357	CcSEcCtD
Atazanavir—Dizziness—Prednisone—multiple sclerosis	9.11e-05	0.000356	CcSEcCtD
Atazanavir—Abdominal pain—Methotrexate—multiple sclerosis	9.1e-05	0.000356	CcSEcCtD
Atazanavir—Body temperature increased—Methotrexate—multiple sclerosis	9.1e-05	0.000356	CcSEcCtD
Atazanavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	8.82e-05	0.0142	CbGpPWpGaD
Atazanavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	8.82e-05	0.0142	CbGpPWpGaD
Atazanavir—Vomiting—Prednisone—multiple sclerosis	8.76e-05	0.000342	CcSEcCtD
Atazanavir—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	8.71e-05	0.014	CbGpPWpGaD
Atazanavir—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	8.71e-05	0.014	CbGpPWpGaD
Atazanavir—Rash—Prednisone—multiple sclerosis	8.68e-05	0.000339	CcSEcCtD
Atazanavir—Dermatitis—Prednisone—multiple sclerosis	8.67e-05	0.000339	CcSEcCtD
Atazanavir—SLCO1B3—Bile acid and bile salt metabolism—ALB—multiple sclerosis	8.66e-05	0.0139	CbGpPWpGaD
Atazanavir—Headache—Prednisone—multiple sclerosis	8.63e-05	0.000337	CcSEcCtD
Atazanavir—Hypersensitivity—Methotrexate—multiple sclerosis	8.48e-05	0.000331	CcSEcCtD
Atazanavir—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	8.47e-05	0.0136	CbGpPWpGaD
Atazanavir—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	8.3e-05	0.0133	CbGpPWpGaD
Atazanavir—Asthenia—Methotrexate—multiple sclerosis	8.26e-05	0.000323	CcSEcCtD
Atazanavir—Nausea—Prednisone—multiple sclerosis	8.18e-05	0.00032	CcSEcCtD
Atazanavir—Pruritus—Methotrexate—multiple sclerosis	8.14e-05	0.000318	CcSEcCtD
Atazanavir—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	8.11e-05	0.0131	CbGpPWpGaD
Atazanavir—Diarrhoea—Methotrexate—multiple sclerosis	7.87e-05	0.000308	CcSEcCtD
Atazanavir—Dizziness—Methotrexate—multiple sclerosis	7.61e-05	0.000297	CcSEcCtD
Atazanavir—Vomiting—Methotrexate—multiple sclerosis	7.32e-05	0.000286	CcSEcCtD
Atazanavir—Rash—Methotrexate—multiple sclerosis	7.26e-05	0.000284	CcSEcCtD
Atazanavir—Dermatitis—Methotrexate—multiple sclerosis	7.25e-05	0.000283	CcSEcCtD
Atazanavir—Headache—Methotrexate—multiple sclerosis	7.21e-05	0.000282	CcSEcCtD
Atazanavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	7.15e-05	0.0115	CbGpPWpGaD
Atazanavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	7.15e-05	0.0115	CbGpPWpGaD
Atazanavir—SLCO1B3—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	7.08e-05	0.0114	CbGpPWpGaD
Atazanavir—Nausea—Methotrexate—multiple sclerosis	6.84e-05	0.000267	CcSEcCtD
Atazanavir—ABCB1—Allograft Rejection—C4A—multiple sclerosis	6.44e-05	0.0104	CbGpPWpGaD
Atazanavir—ABCC1—S1P1 pathway—MAPK1—multiple sclerosis	6.34e-05	0.0102	CbGpPWpGaD
Atazanavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	5.82e-05	0.00936	CbGpPWpGaD
Atazanavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	5.82e-05	0.00936	CbGpPWpGaD
Atazanavir—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	5.74e-05	0.00924	CbGpPWpGaD
Atazanavir—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	5.74e-05	0.00924	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	5.25e-05	0.00845	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	5.25e-05	0.00845	CbGpPWpGaD
Atazanavir—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	5.22e-05	0.0084	CbGpPWpGaD
Atazanavir—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	4.95e-05	0.00796	CbGpPWpGaD
Atazanavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	4.87e-05	0.00783	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	4.78e-05	0.00769	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	4.75e-05	0.00764	CbGpPWpGaD
Atazanavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	4.72e-05	0.00759	CbGpPWpGaD
Atazanavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	4.72e-05	0.00759	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.64e-05	0.00747	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.64e-05	0.00747	CbGpPWpGaD
Atazanavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	4.55e-05	0.00731	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	4.51e-05	0.00725	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	4.09e-05	0.00658	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	3.8e-05	0.00611	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	3.8e-05	0.00611	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.75e-05	0.00603	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.75e-05	0.00603	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.6e-05	0.00579	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	3.55e-05	0.00571	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CD28—multiple sclerosis	3.45e-05	0.00554	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	3.36e-05	0.0054	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	3.3e-05	0.00531	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.28e-05	0.00528	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.28e-05	0.00528	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	3.27e-05	0.00526	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CD40—multiple sclerosis	3.15e-05	0.00506	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	3.1e-05	0.00499	CbGpPWpGaD
Atazanavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	3e-05	0.00482	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—SRM—multiple sclerosis	2.93e-05	0.00472	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.84e-05	0.00458	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	2.83e-05	0.00456	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	2.73e-05	0.00439	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	2.55e-05	0.00411	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.54e-05	0.00409	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.51e-05	0.00405	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	2.51e-05	0.00403	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	2.51e-05	0.00403	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	2.47e-05	0.00397	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	2.47e-05	0.00397	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CD86—multiple sclerosis	2.46e-05	0.00396	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	2.41e-05	0.00388	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL10—multiple sclerosis	2.41e-05	0.00388	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL4—multiple sclerosis	2.35e-05	0.00377	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	2.29e-05	0.00369	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—FAS—multiple sclerosis	2.16e-05	0.00348	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	2.15e-05	0.00346	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	2.13e-05	0.00342	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—SRM—multiple sclerosis	2.07e-05	0.00334	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CYP27B1—multiple sclerosis	2.07e-05	0.00333	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CYP24A1—multiple sclerosis	2.07e-05	0.00333	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.02e-05	0.00325	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.01e-05	0.00324	CbGpPWpGaD
Atazanavir—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.98e-05	0.00319	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	1.94e-05	0.00312	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GPC5—multiple sclerosis	1.89e-05	0.00304	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CD80—multiple sclerosis	1.79e-05	0.00289	CbGpPWpGaD
Atazanavir—SLCO1B3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	1.78e-05	0.00287	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.78e-05	0.00286	CbGpPWpGaD
Atazanavir—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.61e-05	0.00259	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.6e-05	0.00257	CbGpPWpGaD
Atazanavir—ABCC1—Disease—GPC5—multiple sclerosis	1.6e-05	0.00257	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—RRM1—multiple sclerosis	1.57e-05	0.00252	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	1.55e-05	0.0025	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CYP27B1—multiple sclerosis	1.46e-05	0.00235	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CYP24A1—multiple sclerosis	1.46e-05	0.00235	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.46e-05	0.00235	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.46e-05	0.00235	CbGpPWpGaD
Atazanavir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	1.44e-05	0.00232	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.43e-05	0.0023	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	1.42e-05	0.00228	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GPC5—multiple sclerosis	1.34e-05	0.00215	CbGpPWpGaD
Atazanavir—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.31e-05	0.00211	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	1.26e-05	0.00203	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL2—multiple sclerosis	1.26e-05	0.00203	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	1.25e-05	0.00201	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.22e-05	0.00196	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	1.21e-05	0.00195	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—RRM1—multiple sclerosis	1.11e-05	0.00178	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	1.07e-05	0.00172	CbGpPWpGaD
Atazanavir—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.06e-05	0.00171	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.04e-05	0.00168	CbGpPWpGaD
Atazanavir—ABCC1—Disease—RPL5—multiple sclerosis	1.04e-05	0.00167	CbGpPWpGaD
Atazanavir—ABCC1—Disease—SLC11A1—multiple sclerosis	9.94e-06	0.0016	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—SRM—multiple sclerosis	9.87e-06	0.00159	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	9.83e-06	0.00158	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	9.57e-06	0.00154	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.52e-06	0.00153	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—SRM—multiple sclerosis	9.22e-06	0.00148	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—TNF—multiple sclerosis	9.18e-06	0.00148	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.05e-06	0.00146	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—BCHE—multiple sclerosis	9e-06	0.00145	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.59e-06	0.00138	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—POMC—multiple sclerosis	8.55e-06	0.00137	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	8.46e-06	0.00136	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CD28—multiple sclerosis	7.94e-06	0.00128	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.38e-06	0.00119	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CYP24A1—multiple sclerosis	6.95e-06	0.00112	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CYP27B1—multiple sclerosis	6.95e-06	0.00112	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.73e-06	0.00108	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	6.5e-06	0.00105	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	6.5e-06	0.00105	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.4e-06	0.00103	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—BCHE—multiple sclerosis	6.36e-06	0.00102	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GPC5—multiple sclerosis	6.36e-06	0.00102	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.35e-06	0.00102	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—SRM—multiple sclerosis	6.08e-06	0.000978	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GPC5—multiple sclerosis	5.94e-06	0.000956	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CD86—multiple sclerosis	5.66e-06	0.000911	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.64e-06	0.000907	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—APOE—multiple sclerosis	5.41e-06	0.000871	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—RRM1—multiple sclerosis	5.27e-06	0.000848	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CCR5—multiple sclerosis	5.02e-06	0.000808	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—RRM1—multiple sclerosis	4.92e-06	0.000792	CbGpPWpGaD
Atazanavir—ABCC1—Disease—HLA-A—multiple sclerosis	4.9e-06	0.000788	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	4.86e-06	0.000782	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	4.85e-06	0.00078	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	4.76e-06	0.000765	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—POMC—multiple sclerosis	4.65e-06	0.000748	CbGpPWpGaD
Atazanavir—ABCC1—Disease—APOE—multiple sclerosis	4.57e-06	0.000735	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	4.53e-06	0.000729	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.28e-06	0.000689	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.28e-06	0.000689	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—ALB—multiple sclerosis	4.24e-06	0.000682	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CD80—multiple sclerosis	4.13e-06	0.000665	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.92e-06	0.00063	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—APOE—multiple sclerosis	3.83e-06	0.000616	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.82e-06	0.000614	CbGpPWpGaD
Atazanavir—ABCC1—Disease—TYK2—multiple sclerosis	3.49e-06	0.000561	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—POMC—multiple sclerosis	3.29e-06	0.000529	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.28e-06	0.000528	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.25e-06	0.000522	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CD4—multiple sclerosis	3.15e-06	0.000507	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.04e-06	0.00049	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—BCHE—multiple sclerosis	3.03e-06	0.000487	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—ALB—multiple sclerosis	3e-06	0.000482	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.99e-06	0.000481	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—BCHE—multiple sclerosis	2.83e-06	0.000455	CbGpPWpGaD
Atazanavir—ABCC1—Disease—STAT3—multiple sclerosis	2.44e-06	0.000393	CbGpPWpGaD
Atazanavir—ABCC1—Disease—MYC—multiple sclerosis	2.27e-06	0.000365	CbGpPWpGaD
Atazanavir—ABCC1—Disease—TGFB1—multiple sclerosis	2.26e-06	0.000364	CbGpPWpGaD
Atazanavir—ABCC1—Disease—MAPK1—multiple sclerosis	2.22e-06	0.000357	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.86e-06	0.0003	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—APOE—multiple sclerosis	1.82e-06	0.000293	CbGpPWpGaD
Atazanavir—ABCC1—Disease—IL6—multiple sclerosis	1.71e-06	0.000274	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—APOE—multiple sclerosis	1.7e-06	0.000274	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—POMC—multiple sclerosis	1.56e-06	0.000252	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—POMC—multiple sclerosis	1.46e-06	0.000235	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—ALB—multiple sclerosis	1.43e-06	0.000229	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—ALB—multiple sclerosis	1.33e-06	0.000214	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—APOE—multiple sclerosis	1.12e-06	0.00018	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—POMC—multiple sclerosis	9.64e-07	0.000155	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—ALB—multiple sclerosis	8.79e-07	0.000141	CbGpPWpGaD
